-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danegaptide in Diabetic Retinopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danegaptide in Diabetic Retinopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danegaptide in Diabetic Retinopathy Drug Details: Danegaptide is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danegaptide in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danegaptide in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danegaptide in Wet (Neovascular / Exudative) Macular Degeneration...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tonabersat in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tonabersat in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tonabersat in Diabetic Macular Edema Drug Details: Tonabersat (HCB-1019) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tonabersat in Diabetic Nephropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tonabersat in Diabetic Nephropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tonabersat in Diabetic Nephropathy Drug Details: Tonabersat (HCB-1019) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tonabersat in Dry (Atrophic) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tonabersat in Dry (Atrophic) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tonabersat in Dry (Atrophic) Macular Degeneration Drug Details: Tonabersat (HCB-1019)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tonabersat in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tonabersat in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tonabersat in Wet (Neovascular / Exudative) Macular Degeneration...
-
Product Insights
Retinopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Retinopathy - Drugs In Development, 2023’, provides an overview of the Retinopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Retinopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Glaucoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Glaucoma - Drugs In Development, 2023’, provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INexin in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INexin in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INexin in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: aCT11 (alphaCT11)...